SHAREHOLDER ALERT: VRT VLTA ABBV: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you

Vertiv Holdings Co (NYSE:VRT)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/vertiv-holdings-co-loss-submission-form?prid=27553&wire=1
Lead Plaintiff Deadline: May 23, 2022
This lawsuit is on behalf of persons and entities that: (a) purchased or otherwise acquired Vertiv securities between February 24, 2021, and February 23, 2022, inclusive; and/or (b) purchased Vertiv shares in or traceable to the Company's secondary public offering of Class A common stock conducted on or around November 4, 2021.

Allegations against VRT include that: (1) the Company could not adequately respond to supply chain issues and inflation by increasing its prices; (2) as a result of the increasing costs, Vertiv's earnings would be adversely impacted; and (3) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Volta Inc. (NYSE:VLTA)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/volta-inc-loss-submission-form?prid=27553&wire=1
Lead Plaintiff Deadline: May 31, 2022
Class Period: August 2, 2021 - March 28, 2022

Allegations against VLTA include that: (1) Volta had improperly accounted for restricted stock units issued in connection with the business combination of Volta Industries, Inc. ("Legacy Volta") and Tortoise Acquisition Corp. II; (2) as a result, the Company had understated its net loss for third quarter 2021; (3) there were material weaknesses in the Company's internal control over financial reporting that resulted in a material error; (4) as a result of the foregoing, the Company would restate its financial statements; (5) as a result of the foregoing, Legacy Volta's founders would imminently exit the Company; (6) as a result, the Company's financial results would be adversely impacted; and (7) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

AbbVie Inc. (NYSE:ABBV)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/abbvie-inc-loss-submission-form-2?prid=27553&wire=1
Lead Plaintiff Deadline: June 6, 2022
Class Period: April 30, 2021 - August 31, 2021

Allegations against ABBV include that: (1) safety concerns about Pfizer Inc.'s drug Xeljanz extended to ABBVie's drug Rinvoq and to other Janus kinase enzyme inhibitor drugs; (2) as a result, it was likely that the U.S. Food and Drug Administration would require additional safety warnings for Rinvoq and would delay the approval of additional treatment indications for Rinvoq; and (3) therefore, defendants' statements about the Company's business, operations, and prospects lacked a reasonable basis.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE : The Law Offices of Vincent Wong